Bulletin
Investor Alert

New York Markets Open in:

GW Pharmaceuticals PLC ADR

NAS: GWPH

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Mar 2, 2021, 6:15 p.m.

/zigman2/quotes/209686240/composite

$

214.75

Change

-0.14 -0.07%

Volume

Volume 328

Quotes are delayed by 20 min

/zigman2/quotes/209686240/composite

Previous close

$ 214.91

$ 214.89

Change

-0.02 -0.0093%

Day low

Day high

$214.71

$215.22

Open

52 week low

52 week high

$67.98

$217.50

Open

Annual Financials for GW Pharmaceuticals PLC ADR

Fiscal year is January-December. All values USD millions. 20162017201820192020 5-year trend
Sales/Revenue 14.58M10.58M15.49M312.62M531.31M
Cost of Goods Sold (COGS) incl. D&A 9.03M11.64M11.01M27.31M37.82M
COGS excluding D&A 3.84M4.55M1.63M18.03M24.97M
Depreciation & Amortization Expense 5.18M7.09M9.38M9.28M12.86M
Depreciation 5.1M6.78M8.49M8.03M-
Amortization of Intangibles 87,661314,865892,8881.25M-
Gross Income 5.56M(1.06M)4.48M285.31M493.48M
20162017201820192020 5-year trend
SG&A Expense 164.13M188.8M278.63M408.23M545.65M
Research & Development 141.13M142.87M133.49M147.28M206.99M
Other SG&A 23.01M45.93M145.14M260.96M338.66M
Other Operating Expense -----
Unusual Expense -536,177---
EBIT after Unusual Expense -(536,177)---
Non Operating Income/Expense 36.13M(6.48M)(2.13M)102.27M(4M)
Non-Operating Interest Income 859,6392.08M8.91M8.5M1.83M
Equity in Affiliates (Pretax) -----
Interest Expense 244,601956,6681.26M1.09M1.13M
Gross Interest Expense 244,601956,6681.26M1.09M1.13M
Interest Capitalized -----
Pretax Income (121.84M)(195.76M)(268.62M)(13.25M)(55.47M)
Income Tax (31.83M)(26.61M)4.07M(4.19M)3.11M
Income Tax - Current Domestic -2.15M4.06M--
Income Tax - Current Foreign 1.66M--9.55M-
Income Tax - Deferred Domestic (2.82M)(3.2M)8,785--
Income Tax - Deferred Foreign ---(9.74M)-
Income Tax Credits 30.68M25.56M-4.01M-
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (90M)(169.15M)(272.69M)(9.06M)(58.58M)
Minority Interest Expense -----
Net Income (90M)(169.15M)(272.69M)(9.06M)(58.58M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (90M)(169.15M)(272.69M)(9.06M)(58.58M)
Preferred Dividends -----
Net Income Available to Common (90M)(169.15M)(272.69M)(9.06M)(58.58M)
EPS (Basic) (3.99)(6.69)(9.61)(0.29)(1.87)
Basic Shares Outstanding 22.53M25.3M28.37M30.97M31.3M
EPS (Diluted) (3.99)(6.69)(9.61)(0.29)(1.87)
Diluted Shares Outstanding 22.53M25.3M28.37M30.97M31.3M
EBITDA (153.39M)(182.76M)(264.77M)(113.65M)(39.31M)
Link to MarketWatch's Slice.